Liver-specific loss of lipolysis-stimulated lipoprotein receptor triggers systemic hyperlipidemia in mice

Diabetes

Volumn 58, Issue 5, 2009, Pages 1040-1049

  Narvekar, Prachiti ^a   Diaz, Mauricio Berriel ^a   Krones Herzig, Anja ^a   Hardeland, Ulrike ^a   Strzoda, Daniela ^a   Stohr, Sigrid ^b   Frohme, Marcus ^c   Herzig, Stephan ^a  

^a GERMAN CANCER RESEARCH CENTER   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c Technische und forschende Hochschule Wildau   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; CARRIER PROTEIN; CHOLESTEROL; FATTY ACID; GLUCOSE; KETONE BODY; LEPTIN; LIPOLYSIS STIMULATED LIPOPROTEIN RECEPTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; LIPOLYSIS STIMULATED RECEPTOR; LIPOLYSIS-STIMULATED RECEPTOR; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HYPERLIPIDEMIA; INSULIN TOLERANCE TEST; LIPID DIET; LIPID LIVER LEVEL; LIPID TRANSPORT; LIVER CELL CULTURE; MALE; METABOLIC SYNDROME X; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; GENETICS; LIPOLYSIS; LIVER; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

ANIMALS; APOLIPOPROTEINS E; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FATTY ACIDS, NONESTERIFIED; HYPERLIPIDEMIAS; KETONE BODIES; LIPOLYSIS; LIPOPROTEINS, VLDL; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, OBESE; RECEPTORS, LDL; RECEPTORS, LIPOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRIGLYCERIDES;

EID: 65549093979     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db08-1184     Document Type: Article

References (41)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14(Suppl. 5):S1-S85
2. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820
3. Chahil TJ, Ginsberg HN. Diabetic dyslipidemia. Endocrinol Metab Clin North Am 2006;35:491-510, vii-viii
4. Ginsberg HN. Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes 1996;45(Suppl. 3):S27-S30
5. Duval C, Muller M, Kersten S. PPARα and dyslipidemia. Biochim Biophys Acta 2007;1771:961-971
6. Havel RJ. Chylomicron remnants: hepatic receptors and metabolism. Curr Opin Lipidol 1995;6:312-316
7. Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK. Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J 1988;7:4119-4127
8. Rohlmann A, Gotthardt M, Hammer RE, Herz J. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest 1998;101:689-695
9. Herz J, Qiu SQ, Oesterle A, DeSilva HV, Shafi S, Havel RJ. Initial hepatic removal of chylomicron remnants is unaffected but endocytosis is delayed in mice lacking the low density lipoprotein receptor. Proc Natl Acad Sci USA 1995;92:4611-4615
10. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993;92:883-893
11. Out R, Hoekstra M, de Jager SC, de Vos P, van der Westhuyzen DR, Webb NR, Van Eck M, Biessen EA, Van Berkel TJ. Adenovirus-mediated hepatic overexpression of scavenger receptor class B type I accelerates chylomicron metabolism in C57BL/6J mice. J Lipid Res 2005;46:1172- 1181, 2005
12. Mann CJ, Khallou J, Chevreuil O, Troussard AA, Guermani LM, Launay K, Delplanque B, Yen FT, Bihain BE. Mechanism of activation and functional significance of the lipolysis-stimulated receptor: evidence for a role as chylomicron remnant receptor. Biochemistry 1995;34:10421-10431
13. Mann CJ, Troussard AA, Yen FT, Hannouche N, Najib J, Fruchart JC, Lotteau V, Andre P, Bihain BE. Inhibitory effects of specific apolipopro- tein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor. J Biol Chem 1997;272:31348-31354
14. Troussard AA, Khallou J, Mann CJ, Andre P, Strickland DK, Bihain BE, Yen FT. Inhibitory effect on the lipolysis-stimulated receptor of the 39-kDa receptor-associated protein. J Biol Chem 1995;270:17068-17071
15. Yen FT, Masson M, Clossais-Besnard N, Andre P, Grosset JM, Bougueleret L, Dumas JB, Guerassimenko O, Bihain BE. Molecular cloning of a lipolysis-stimulated remnant receptor expressed in the liver. J Biol Chem 1999;274:13390-13398
16. Yen FT, Roitel O, Bonnard L, Notet V, Pratte D, Stenger C, Magueur E, Bihain BE. Lipolysis stimulated lipoprotein receptor: a novel molecular link between hyperlipidemia, weight gain and atherosclerosis in mice. J Biol Chem 2008;283:25650-35659
17. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Aleman JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, Cohen DE, King GL, Ginsberg HN, Kahn CR. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 2008;7:125-134
18. Becker TC, Noel RJ, Coats WS, Gomez-Foix AM, Alam T, Gerard RD, Newgard CB. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol 1994;43(Pt. A):161-189
19. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, Kahn CR. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000; 6:87-97
20. Dhahbi JM, Mote PL, Cao SX, Spindler SR. Hepatic gene expression profiling of streptozotocin-induced diabetes. Diabetes Technol Ther 2003; 5:411-420
21. Mandard S, Zandbergen F, van Straten E, Wahli W, Kuipers F, Muller M, Kersten S. The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J Biol Chem 2006;281:934-944
22. Lichtenstein L, Berbee JF, van Dijk SJ, van Dijk KW, Bensadoun A, Kema IP, Voshol PJ, Muller M, Rensen PC, Kersten S. Angptl4 upregulates cholesterol synthesis in liver via inhibition of LPL- and HL-dependent hepatic cholesterol uptake. Arterioscler Thromb Vasc Biol 2007;27:2420-2427
23. Lee Y, Wang MY, Kakuma T, Wang ZW, Babcock E, McCorkle K, Higa M, Zhou YT, Unger RH. Liporegulation in diet-induced obesity: the antistea- totic role of hyperleptinemia. J Biol Chem 2001;276:5629-5635
24. Klingenspor M, Klaus S, Wiesinger H, Heldmaier G. Short photoperiod and cold activate brown fat lipoprotein lipase in the Djungarian hamster. Am J Physiol 1989;257:R1123-R1127
25. Herzig S, Long F, Jhala US, Hedrick S, Quinn R, Bauer A, Rudolph D, Schutz G, Yoon C, Puigserver P, Spiegelman B, Montminy M. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 2001;413:179-183
26. Klingmuller U, Bauer A, Bohl S, Nickel PJ, Breitkopf K, Dooley S, Zellmer S, Kern C, Merfort I, Sparna T, Donauer J, Walz G, Geyer M, Kreutz C, Hermes M, Gotschel F, Hecht A, Walter D, Egger L, Neubert K, Borner C, Brulport M, Schormann W, Sauer C, Baumann F, Preiss R, MacNelly S, Godoy P, Wiercinska E, Ciuclan L, Edelmann J, Zeilinger K, Heinrich M, Zanger UM, Gebhardt R, Maiwald T, Heinrich R, Timmer J, von Weizsacker F, Hengstler JG. Primary mouse hepatocytes for systems biology approaches: a standardized in vitro system for modelling of signal transduction pathways. IEE Syst Biol 2006;153:433-447
27. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996;84:491-495
28. Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci USA 1997;94:12610-12615
29. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269:540-543
30. Leiter EH, Reifsnyder PC. Differential levels of diabetogenic stress in two new mouse models of obesity and type 2 diabetes. Diabetes 2004; 53(Suppl.)1:S4-S11
31. Mesli S, Javorschi S, Berard AM, Landry M, Priddle H, Kivlichan D, Smith AJ, Yen FT, Bihain BE, Darmon M. Distribution of the lipolysis stimulated receptor in adult and embryonic murine tissues and lethality of LSR-I- embryos at 12.5 to 14.5 days of gestation. Eur J Biochem 2004;271:3103-3114
32. Saad MJ, Araki E, Miralpeix M, Rothenberg PL, White MF, Kahn CR. Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance. J Clin Invest 1992;90:1839-1849
33. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF. Serum immunoreactive- leptin concentrations in normal-weight and obese humans. N Engl J Med 1995;334:292-295
34. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM. Weight-reducing effects ofthe plasma protein encoded by the obese gene. Science 1995;269:543-546
35. Igel M, Becker W, Herberg L, Joost HG. Hyperleptinemia, leptin resistance, and polymorphic leptin receptor in the New Zealand obese mouse. Endocrinology 1997;138:4234-4239
36. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992;71:343-353
37. Silver DL, Jiang XC, Tall AR. Increased high density lipoprotein (HDL), defective hepatic catabolism of ApoA-I and ApoA-II, and decreased ApoA-I mRNA in ob/ob mice. Possible role of leptin in stimulation of HDL turnover. J Biol Chem 1999;274:4140-4146
38. Bihain BE, Yen FT. Free fatty acids activate a high-affinity saturable pathway for degradation of low-density lipoproteins in fibroblasts from a subject homozygous for familial hypercholesterolemia. Biochemistry 1992; 31:4628-4636
39. Yen FT, Mann CJ, Guermani LM, Hannouche NF, Hubert N, Hornick CA, Bordeau VN, Agnani G, Bihain BE. Identification of a lipolysis-stimulated receptor that is distinct from the LDL receptor and the LDL receptor-related protein. Biochemistry 1994;33:1172-1180
40. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 1990;249:790-793
41. Ueda Y, Royer L, Gong E, Zhang J, Cooper PN, Francone O, Rubin EM. Lower plasma levels and accelerated clearance of high density lipoprotein (HDL) and non-HDL cholesterol in scavenger receptor class B type I transgenic mice. J Biol Chem 1999;274:7165-7171